Incyte Q2 product revenue up 25% to $827M; raises Jakafi guidance; CSO departs

INCYTE CORP

2023-Q2 EPS reported $1.00 revenue$1,763,283,000

Total net product revenue $827M (+25% YoY); Jakafi $682M (+14%), Opzelura $80M (+384%).
Raises Jakafi FY 2023 revenue guidance low end to $2.58-2.63B (from $2.55-2.63B).
Two pivotal trials met endpoints: ruxolitinib cream in pediatric AD (TRuE-AD3) and axatilimab in chronic GVHD (AGAVE-201).
CSO Dr. Dashyant Dhanak leaving effective Aug 2, 2023; oversaw 15+ IND filings during tenure.

item 2.02 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.92

INCYTE CORP reported second fiscal quarter ended June 30, 2023 results: revenue Total net product revenues of $827 million in the second quarter (Q2'23). Guidance raised.

Period: second fiscal quarter ended June 30, 2023
Revenue: Total net product revenues of $827 million in the second quarter (Q2'23)
Guidance: raised
Result: reported results

Exact text from the filing

Incyte Reports 2023 Second Quarter Financial Results and Provides Updates on Key Clinical Programs – Total net product revenues of $827 million in the second quarter (Q2'23) (+25% Y/Y) – Jakafi ® (ruxolitinib) net product revenues of $682 million (+14% Y/Y) in Q2'23; raising the bottom end of full year guidance to a new range of $2.58 - $2.63 billion for FY 2023

View on SEC.gov

Browse all earnings releases →

INCYTE CORP filing history →

Source: SEC EDGAR

accession 0000879169-23-000022

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.